Trial Profile
Abiraterone Acetate Treatment for Prostate Cancer Patients With a PSA of More Than Four Following Initial Androgen Deprivation Therapy Phase II
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2023
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Degarelix; Goserelin; Leuprorelin; Prednisone
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Therapeutic Use
- 30 Nov 2022 Planned End Date changed from 1 Oct 2022 to 1 Oct 2023.
- 29 Nov 2021 Planned End Date changed from 1 Oct 2021 to 1 Oct 2022.
- 06 Dec 2019 Planned End Date changed from 1 Oct 2019 to 1 Oct 2021.